Recombinant human erythropoietin in the treatment of nonrenal anemia

Annals of Hematology

Volumn 85, Issue 2, 2006, Pages 69-78

  Heuser, Michael ^a   Ganser, Arnold ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Anemia; Bone marrow transplantation; Cancer; Chemotherapy; Critical care; Erythropoietin; Myelodysplastic syndrome; Surgery

Indexed keywords

AMINOCAPROIC ACID; ANDROGEN; ANTINEOPLASTIC AGENT; CORTICOSTEROID; CYCLOPHOSPHAMIDE; GRANULOCYTE COLONY STIMULATING FACTOR; HYDROXYUREA; IMMUNOGLOBULIN; IRON; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PLACEBO; RECOMBINANT ERYTHROPOIETIN; STEROID; ZIDOVUDINE;

ANEMIA; BETA THALASSEMIA; BONE MARROW TRANSPLANTATION; CANCER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DIARRHEA; DRUG APPROVAL; DRUG COST; DRUG EFFICACY; DRUG HALF LIFE; DRUG MEGADOSE; EDEMA; ERYTHROCYTE TRANSFUSION; GRAFT VERSUS HOST REACTION; HEART INFARCTION; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERTENSION; INTENSIVE CARE; META ANALYSIS; MYELODYSPLASTIC SYNDROME; MYELOID METAPLASIA; NONHUMAN; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PURE RED CELL ANEMIA; RELIABILITY; REVIEW; RISK FACTOR; SICKLE CELL ANEMIA; SYSTEMATIC REVIEW; THROMBOSIS; TREATMENT INDICATION;

ANEMIA; BONE MARROW TRANSPLANTATION; CLINICAL TRIALS; CLINICAL TRIALS AS TOPIC; COST-BENEFIT ANALYSIS; ERYTHROPOIETIN, RECOMBINANT; FEMALE; HUMANS; MALE; MYELODYSPLASTIC SYNDROMES; NEOPLASMS;

EID: 30644467245     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00277-005-1086-5     Document Type: Review

References (105)

1. Cartwright GE, Wintrobe MM (1952) The anemia of infection. XVII. A review. Adv Intern Med 5:165-226 12996335 (abstr)
2. Bron D, Meuleman N, Mascaux C (2001) Biological basis of anemia. Semin Oncol 28:1-6 10.1016/S0093-7754(01)90205-2
3. Bertero MT, Caligaris-Cappio F (1997) Anemia of chronic disorders in systemic autoimmune diseases. Haematologica 82:375-381 9234597
4. Miller CB, Jones RJ, Piantadosi S, Abeloff MD, Spivak JL (1990) Decreased erythropoietin response in patients with the anemia of cancer. N Engl J Med 322:1689-1692 2342534
5. Spivak JL (1994) Cancer-related anemia: Its causes and characteristics. Semin Oncol 21:3-8
6. Janatpour K, Holland PV (2002) Noninfectious serious hazards of transfusion. Curr Hematol Rep 1:149-155 12901137 (abstr)
7. Uhl L (2005) Infectious risks of blood transfusion. Curr Hematol Rep 1:156-162 (abstr)
8. Rizzo JD, Lichtin AE, Woolf SH et al (2002) Use of epoetin in patients with cancer: Evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. Blood 100:2303-2320 10.1182/blood-2002-06-1767
9. Wu H, Liu X, Jaenisch R, Lodish HF (1995) Generation of committed erythroid BFU-E and CFU-E progenitors does not require erythropoietin or the erythropoietin receptor. Cell 83:59-67 10.1016/0092-8674(95)90234-1
10. Anagnostou A, Liu Z, Steiner M et al (1994) Erythropoietin receptor mRNA expression in human endothelial cells. Proc Natl Acad Sci U S A 91:3974-3978 8171022
11. Ribatti D, Presta M, Vacca A et al (1999) Human erythropoietin induces a pro-angiogenic phenotype in cultured endothelial cells and stimulates neovascularization in vivo. Blood 93:2627-2636 10194442
12. Weber A, Maier RF, Hoffmann U et al (2002) Erythropoietin improves synaptic transmission during and following ischemia in rat hippocampal slice cultures. Brain Res 958:305-311 10.1016/S0006-8993(02)03604-1
13. Celik M, Gokmen N, Erbayraktar S et al (2002) Erythropoietin prevents motor neuron apoptosis and neurologic disability in experimental spinal cord ischemic injury. Proc Natl Acad Sci U S A 99:2258-2263 10.1073/ pnas.042693799
14. Storring PL, Tiplady RJ, Gaines Das RE et al (1998) Epoetin alfa and beta differ in their erythropoietin isoform compositions and biological properties. Br J Haematol 100:79-89 10.1046/j.1365-2141.1998.00521.x
15. Ibbotson T, Goa KL (2001) Darbepoetin alfa. Drugs 61:2097-2104 11735636
16. Rizzo JD, Lichtin AE, Woolf SH et al (2002) Use of epoetin in patients with cancer: Evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. J Clin Oncol 20:4083-4107 10.1200/JCO.2002.07.177
17. Witzig TE, Silberstein PT, Loprinzi CL et al (2005) Phase III, randomized, double-blind study of epoetin alfa versus placebo in anemic patients with cancer undergoing chemotherapy. J Clin Oncol 23:2606-2617 10.1200/JCO.2004.10.020
18. Jadoul M, Vanrenterghem Y, Foret M, Walker R, Gray SJ (2004) Darbepoetin alfa administered once monthly maintains haemoglobin levels in stable dialysis patients. Nephrol Dial Transplant 19:898-903 10.1093/ndt/gfh021
19. Waltzman R, Williams D (2004) Head-to-head comparison of epoetin alfa (EPO) 40,000 U QW vs. darbepoetin alfa (DARB) 200μg Q2W in anemic cancer patients receiving chemotherapy (CT): Final results of a planned interim analysis (IA). Blood 104 abstract #4233 abstract #4233
20. Glaspy JA, Jadeja JS, Justice G et al (2002) Darbepoetin alfa given every 1 or 2 weeks alleviates anaemia associated with cancer chemotherapy. Br J Cancer 87:268-276 10.1038/sj.bjc.6600465
21. Glaspy JA, Jadeja JS, Justice G, Fleishman A, Rossi G, Colowick AB (2003) A randomized, active-control, pilot trial of front-loaded dosing regimens of darbepoetin-alfa for the treatment of patients with anemia during chemotherapy for malignant disease. Cancer 97:1312-1320 10.1002/ cncr.11186
22. Smith KJ, Bleyer AJ, Little WC, Sane DC (2003) The cardiovascular effects of erythropoietin. Cardiovasc Res 59:538-548 10.1016/ S0008-6363(03)00468-1
23. Document. Summary for basis of approval, epoetin alfa (Amgen)
24. Bohlius J, Langensiepen S, Schwarzer G et al (2004) Erythropoietin for patients with malignant disease. Cochrane Database Syst Rev CD003407
25. Besarab A, Bolton WK, Browne JK et al (1998) The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 339:584-590 10.1056/ NEJM199808273390903
26. Leyland-Jones B (2003) Breast cancer trial with erythropoietin terminated unexpectedly. Lancet Oncol 4:459-460 10.1016/ S1470-2045(03)01163-X
27. Peces R, de la Torre M, Alcazar R, Urra JM (1996) Antibodies against recombinant human erythropoietin in a patient with erythropoietin-resistant anemia. N Engl J Med 335:523-524 10.1056/ NEJM199608153350717
28. Rossert J, Casadevall N, Eckardt KU (2004) Anti-erythropoietin antibodies and pure red cell aplasia. J Am Soc Nephrol 15:398-406 10.1097/01.ASN.0000107561.59698.42
29. Gershon SK, Luksenburg H, Cote TR, Braun MM (2002) Pure red-cell aplasia and recombinant erythropoietin. N Engl J Med 346:1584-1586 10.1056/ NEJM200205163462015
30. Bennett CL, Luminari S, Nissenson AR et al (2004) Pure red-cell aplasia and epoetin therapy. N Engl J Med 351:1403-1408 10.1056/NEJMoa040528
31. Locatelli F, Del Vecchio L (2003) Pure red cell aplasia secondary to treatment with erythropoietin. Artif Organs 27:755-758 10.1046/ j.1525-1594.2003.00991.x
32. Schellekens H (2002) Immunogenicity of therapeutic proteins: Clinical implications and future prospects. Clin Ther 24:1720-1740 10.1016/ S0149-2918(02)80075-3
33. Casadevall N, Nataf J, Viron B et al (2002) Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med 346:469-475 10.1056/NEJMoa011931
34. Verhelst D, Rossert J, Casadevall N, Kruger A, Eckardt KU, Macdougall IC (2004) Treatment of erythropoietin-induced pure red cell aplasia: A retrospective study. Lancet 363:1768-1771 10.1016/S0140-6736(04)16302-2
35. Groopman JE, Itri LM (1999) Chemotherapy-induced anemia in adults: incidence and treatment. J Natl Cancer Inst 91:1616-1634 10.1093/jnci/ 91.19.1616
36. Knight K, Wade S, Balducci L (2004) Prevalence and outcomes of anemia in cancer: A systematic review of the literature. Am J Med 116(Suppl 7A):11S-26S 10.1016/j.amjmed.2003.12.008
37. Glaser CM, Millesi W, Kornek GV et al (2001) Impact of hemoglobin level and use of recombinant erythropoietin on efficacy of preoperative chemoradiation therapy for squamous cell carcinoma of the oral cavity and oropharynx. Int J Radiat Oncol Biol Phys 50:705-715 10.1016/ S0360-3016(01)01488-2
38. Seidenfeld J, Piper M, Flamm C et al (2001) Epoetin treatment of anemia associated with cancer therapy: A systematic review and meta-analysis of controlled clinical trials. J Natl Cancer Inst 93:1204-1214 10.1093/jnci/ 93.16.1204
39. Witzig TE, Silberstein PT, Loprinzi CL et al (2005) Phase III, randomized, double-blind study of epoetin alfa compared with placebo in anemic patients receiving chemotherapy. J Clin Oncol 23:2606-2617 10.1200/JCO.2004.10.020
40. Bokemeyer C, Aapro MS, Courdi A et al (2004) EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer. Eur J Cancer 40:2201-2216 10.1016/j.ejca.2004.07.015
41. Dammacco F, Castoldi G, Rodjer S (2001) Efficacy of epoetin alfa in the treatment of anaemia of multiple myeloma. Br J Haematol 113:172-179 10.1046/j.1365-2141.2001.02715.x
42. Osterborg A, Brandberg Y, Molostova V et al (2002) Randomized, double-blind, placebo-controlled trial of recombinant human erythropoietin, epoetin beta, in hematologic malignancies. J Clin Oncol 20:2486-2494 10.1200/JCO.2002.08.131
43. Vansteenkiste J, Pirker R, Massuti B et al (2002) Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. J Natl Cancer Inst 94:1211-1220 12189224
44. Hedenus M, Adriansson M, San Miguel J et al (2003) Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: A randomized, double-blind, placebo-controlled study. Br J Haematol 122:394-403 10.1046/j.1365-2141.2003.04448.x
45. Auerbach M, Ballard H, Trout JR et al (2004) Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: A multicenter, open-label, randomized trial. J Clin Oncol 22:1301-1307 10.1200/JCO.2004.08.119
46. Ganser A (1995) Hematopoietic growth factors in the treatment of the myelodysplastic syndromes. Curr Opin Hematol 2:204-209 9371996
47. Beguin Y (2002) Prediction of response and other improvements on the limitations of recombinant human erythropoietin therapy in anemic cancer patients. Haematologica 87:1209-1221 12414352
48. Smith RE Jr, Tchekmedyian NS, Chan D et al (2003) A dose- and schedule-finding study of darbepoetin alpha for the treatment of chronic anaemia of cancer. Br J Cancer 88:1851-1858 10.1038/sj.bjc.6600994
49. Abels RI, Larholt KM, Krantz KD, Bryant EC (1996) Recombinant human erythropoietin (rHuEPO) for the treatment of the anemia of cancer. Oncologist 1:140-150 10387980
50. Quirt I, Robeson C, Lau CY et al (2001) Epoetin alfa therapy increases hemoglobin levels and improves quality of life in patients with cancer-related anemia who are not receiving chemotherapy and patients with anemia who are receiving chemotherapy. J Clin Oncol 19:4126-4134 11689580
51. Daneryd P, Svanberg E, Korner U et al (1998) Protection of metabolic and exercise capacity in unselected weight-losing cancer patients following treatment with recombinant erythropoietin: A randomized prospective study. Cancer Res 58:5374-5379 9850068
52. Pangalis GA, Siakantaris MP, Angelopoulou MK et al (2002) Downstaging Rai stage III B-chronic lymphocytic leukemia patients with the administration of recombinant human erythropoietin. Haematologica 87:500-506 12010663
53. Niscola P, Scaramucci L, Bongarzoni V, Montanero M (2002) Management of disease-related anemia by high-doses of epoetin alfa in patients with multiple myeloma. Blood 100 abstract #5111 (abstr)
54. Link H, Boogaerts MA, Fauser AA et al (1994) A controlled trial of recombinant human erythropoietin after bone marrow transplantation. Blood 84:3327-3335 7949088
55. Vannucchi AM, Bosi A, Ieri A et al (1996) Combination therapy with G-CSF and erythropoietin after autologous bone marrow transplantation for lymphoid malignancies: A randomized trial. Bone Marrow Transplant 17:527-531 8722349
56. Chao NJ, Schriber JR, Long GD et al (1994) A randomized study of erythropoietin and granulocyte colony-stimulating factor (G-CSF) versus placebo and G-CSF for patients with Hodgkin's and non-Hodgkin's lymphoma undergoing autologous bone marrow transplantation. Blood 83:2823-2828 7514046
57. Ballen KK, Becker PS, Yeap BY, Matthews B, Henry DH, Ford PA (2004) Autologous stem-cell transplantation can be performed safely without the use of blood-product support. J Clin Oncol 22 4087-4094 10.1200/ JCO.2004.01.144
58. Biggs JC, Atkinson KA, Booker V et al (1995) Prospective randomised double-blind trial of the in vivo use of recombinant human erythropoietin in bone marrow transplantation from HLA-identical sibling donors. The Australian bone marrow transplant study group. Bone Marrow Transplant 15:129-134 7742745
59. A randomized double-blind placebo-controlled study with subcutaneous recombinant human erythropoietin in patients with low-risk myelodysplastic syndromes. Italian cooperative study group for rHuEpo in melodysplastic syndromes. (1998) Br J Haematol 103:1070-1074 10.1046/ j.1365-2141.1998.01085.x
60. Terpos E, Mougiou A, Kouraklis A et al (2002) Prolonged administration of erythropoietin increases erythroid response rate in myelodysplastic syndromes: A phase II trial in 281 patients. Br J Haematol 118:174-180 10.1046/j.1365-2141.2002.03583.x
61. Ganser A, Karthaus M (1997) Clinical use of hematopoietic growth factors in the myelodysplastic syndromes. Leuk Lymphoma 26(Suppl 1):13-27 9570676
62. Musto P, Lanza F, Balleari E et al (2005) Darbepoetin alpha for the treatment of anaemia in low-intermediate risk myelodysplastic syndromes. Br J Haematol 128:204-209 10.1111/j.1365-2141.2004.05288.x
63. Rose EH, Abels RI, Nelson RA, McCullough DM, Lessin L (1995) The use of r-HuEpo in the treatment of anaemia related to myelodysplasia (MDS). Br J Haematol 89:831-837 7772519
64. Negrin RS, Stein R, Doherty K et al (1996) Maintenance treatment of the anemia of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor and erythropoietin: Evidence for in vivo synergy. Blood 87:4076-4081 8639764
65. Negrin RS, Stein R, Vardiman J et al (1993) Treatment of the anemia of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor and erythropoietin: Evidence for in vivo synergy. Blood 87:4076-4081
66. Hellstrom-Lindberg E, Ahlgren T, Beguin Y et al (1998) Treatment of anemia in myelodysplastic syndromes with granulocyte colony-stimulating factor plus erythropoietin: Results from a randomized phase II study and long-term follow-up of 71 patients. Blood 92:68-75 9639501
67. Hellstrom-Lindberg E, Negrin R, Stein R et al (1997) Erythroid response to treatment with G-CSF plus erythropoietin for the anaemia of patients with myelodysplastic syndromes: Proposal for a predictive model. Br J Haematol 99:344-351
68. Casadevall N, Durieux P, Dubois S et al (2004) Health, economic, and quality-of-life effects of erythropoietin and granulocyte colony-stimulating factor for the treatment of myelodysplastic syndromes: A randomized, controlled trial. Blood 104:321-327
69. Jadersten M, Montgomery SM, Dybedal I, Porwit-Macdonald A, Hellstrom-Lindberg E (2005) Long-term outcome of treatment of anemia in MDS with erythropoietin and G-CSF. Blood Epub Apr 19; 0: 200410387
70. Thompson JA, Gilliland DG, Prchal JT et al (2000) Effect of recombinant human erythropoietin combined with granulocyte/macrophage colony-stimulating factor in the treatment of patients with myelodysplastic syndrome. GM/EPO MDS study group. Blood 95:117-1179
71. Aloe SM, Latagliata R, Avvisati G et al (1993) Erythropoietin treatment of idiopathic myelofibrosis. Haematologica 78:371-373
72. Tefferi A, Silverstein MN (1994) Recombinant human erythropoietin therapy in patients with myelofibrosis with myeloid metaplasia. Br J Haematol 86:893
73. Rodriguez JN, Martino ML, Dieguez JC, Prados D (1998) rHuEpo for the treatment of anemia in myelofibrosis with myeloid metaplasia. Experience in 6 patients and meta-analytical approach. Haematologica 83:616-621
74. Mohr B, Herrmann R, Huhn D (1993) Recombinant human erythropoietin in patients with myelodysplastic syndrome and myelofibrosis. Acta Haematol 90:65-70
75. Tefferi A (2003) Treatment approaches in myelofibrosis with myeloid metaplasia: The old and the new. Semin Hematol 40:18-21
76. Halperin DS, Freedman MH (1989) Diamond-blackfan anemia: Etiology, pathophysiology, and treatment. Am J Pediatr Hematol/Oncol 11:380-394
77. Niemeyer CM, Baumgarten E, Holldack J et al (1991) Treatment trial with recombinant human erythropoietin in children with congenital hypoplastic anemia. Contrib Nephrol 88:276-280 discussion 281.:276-80
78. Gillio AP, Faulkner LB, Alter BP et al (1993) Successful treatment of Diamond-Blackfan anemia with interleukin 3. Stem Cells 11(Suppl 2):123-130
79. Vellenga E, de Wolf JT, Halie MR (1989) Recombinant erythropoietin failed to correct anemia in Fanconi syndrome. Leukemia 3:858
80. Bessho M, Hirashima K, Asano S et al (1997) Treatment of the anemia of aplastic anemia patients with recombinant human erythropoietin in combination with granulocyte colony-stimulating factor: A multicenter randomized controlled study. Multicenter study group. Eur J Haematol 58:265-272
81. Shao Z, Chu Y, Zhang Y, Chen G, Zheng Y (1998) Treatment of severe aplastic anemia with an immunosuppressive agent plus recombinant human granulocyte-macrophage colony-stimulating factor and erythropoietin. Am J Hematol 59:185-191
82. Boschetti C, Fermo E, Bianchi P, Vercellati C, Barraco F, Zanella A (2004) Clinical and molecular aspects of 23 patients affected by paroxysmal nocturnal hemoglobinuria. Am J Hematol 77:36-44
83. Rodgers GP, Dover GJ, Uyesaka N, Noguchi CT, Schechter AN, Nienhuis AW (1993) Augmentation by erythropoietin of the fetal-hemoglobin response to hydroxyurea in sickle cell disease. N Engl J Med 328:73-80
84. al Khatti A, Umemura T, Clow J et al (1988) Erythropoietin stimulates F-reticulocyte formation in sickle cell anemia. Trans Assoc Am Physicians 101:54-61
85. Nagel RL, Vichinsky E, Shah M et al (1993) F reticulocyte response in sickle cell anemia treated with recombinant human erythropoietin: A double-blind study. Blood 81:9-14
86. Goldberg MA, Brugnara C, Dover GJ, Schapira L, Charache S, Bunn HF (1990) Treatment of sickle cell anemia with hydroxyurea and erythropoietin. N Engl J Med 323:366-372
87. Rachmilewitz EA, Aker M, Perry D, Dover G (1995) Sustained increase in haemoglobin and RBC following long-term administration of recombinant human erythropoietin to patients with homozygous beta-thalassaemia. Br J Haematol 90:341-345
88. Nisli G, Kavakli K, Aydinok Y, Oztop S, Cetingul N, Basak N (1997) Recombinant erythropoietin trial in children with transfusion-dependent homozygous beta-thalassemia. Acta Haematol 98:199-203
89. Chaidos A, Makis A, Hatzimichael E et al (2004) Treatment of beta-thalassemia patients with recombinant human erythropoietin: Effect on transfusion requirements and soluble adhesion molecules. Acta Haematol 111:189-195
90. Scientific discussion (2004) http://www.emea.eu.int/humandocs/Humans/ EPAR/neorecormon/neorecormon.htm
91. de Andrade JR, Jove M, Landon G, Frei D, Guilfoyle M, Young DC (1996) Baseline hemoglobin as a predictor of risk of transfusion and response to epoetin alfa in orthopedic surgery patients. Am J Orthop 25:533-542
92. Epoetin alfa-product approval information (2004) http://www.fda.gov/cder/ foi/label/2004/103234_5053_Epogen_lbl.pdf
93. Atabek U, Alvarez R, Pello MJ et al (1995) Erythropoetin accelerates hematocrit recovery in post-surgical anemia. Am Surg 61:74-77
94. Corwin HL, Gettinger A, Rodriguez RM et al (1999) Efficacy of recombinant human erythropoietin in the critically ill patient: A randomized, double-blind, placebo-controlled trial. Crit Care Med 27:2346-2350
95. Corwin HL, Gettinger A, Pearl RG et al (2002) Efficacy of recombinant human erythropoietin in critically ill patients: A randomized controlled trial. JAMA 288:2827-2835 10.1001/jama.288.22.2827
96. von Ahsen N, Muller C, Serke S, Frei U, Eckardt KU (1999) Important role of nondiagnostic blood loss and blunted erythropoietic response in the anemia of medical intensive care patients. Crit Care Med 27:2630-2639 10.1097/00003246-199912000-00005
97. Vincent JL, Baron JF, Reinhart K et al (2002) Anemia and blood transfusion in critically ill patients. JAMA 288:1499-1507 10.1001/ jama.288.12.1499
98. Silver DF, Piver MS (1999) Effects of recombinant human erythropoietin on the antitumor effect of cisplatin in SCID mice bearing human ovarian cancer: A possible oxygen effect. Gynecol Oncol 73:280-284 10.1006/ gyno.1999.5368
99. Thews O, Koenig R, Kelleher DK, Kutzner J, Vaupel P (1998) Enhanced radiosensitivity in experimental tumours following erythropoietin treatment of chemotherapy-induced anaemia. Br J Cancer 78:752-756 9743294
100. Littlewood TJ, Bajetta E, Nortier JW, Vercammen E, Rapoport B (2001) Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: Results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 19:2865-2874 11387359
101. Bohlius J, Langensiepen S, Schwarzer G et al (2005) Recombinant human erythropoietin and overall survival in cancer patients: Results of a comprehensive meta-analysis. J Natl Cancer Inst 97:489-498 15812074
102. Henke M, Laszig R, Rube C et al (2003) Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: Randomised, double-blind, placebo-controlled trial. Lancet 362:1255-1260 10.1016/ S0140-6736(03)14567-9
103. Brower V (2003) Erythropoietin may impair, not improve, cancer survival. Nat Med 9:1439 Brower V (2003) Erythropoietin may impair, not improve, cancer survival. Nat Med 9:1439 10.1038/nm1203-1439
104. Marchetti M, Barosi G (2004) Clinical and economic impact of epoetins in cancer care. Pharmacoeconomics 22:1029-1045 15524492
105. American Society of Clinical Oncology (1996) Outcomes of cancer treatment for technology assessment and cancer treatment guidelines. J Clin Oncol 14:671-679 American Society of Clinical Oncology